$KPTI
Karyopharm Therapeutics Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023017483 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $37.58M $38.70M $47.67M
YoY Change -5.29% -18.82% 104.94%
Cost Of Revenue $1.194M $1.351M $1.426M
YoY Change 27.16% -5.26% 53.33%
Gross Profit $36.39M $37.35M $46.24M
YoY Change -6.08% -19.24% 107.09%
Gross Profit Margin 96.82% 96.51% 97.01%
Selling, General & Admin $34.48M $35.91M $38.77M
YoY Change -7.65% -7.38% 2.97%
% of Gross Profit 94.77% 96.14% 83.83%
Research & Development $31.48M $32.34M $42.06M
YoY Change -28.96% -23.12% 13.53%
% of Gross Profit 86.51% 86.59% 90.96%
Depreciation & Amortization $83.00K $290.0K $177.0K
YoY Change -44.3% 63.84% -24.68%
% of Gross Profit 0.23% 0.78% 0.38%
Operating Expenses $65.96M $69.60M $82.26M
YoY Change -20.14% -15.39% 8.76%
Operating Profit -$29.57M -$30.90M -$34.59M
YoY Change -31.08% -10.66% -33.96%
Interest Expense -$2.960M $5.758M $6.684M
YoY Change -146.89% -13.85% 31.19%
% of Operating Profit
Other Income/Expense, Net $30.00K -$3.173M -$6.683M
YoY Change -100.5% -52.52% 36.61%
Pretax Income -$32.50M -$34.07M -$41.27M
YoY Change -33.59% -17.44% -27.93%
Income Tax $127.0K $54.00K $130.0K
% Of Pretax Income
Net Earnings -$32.63M -$34.13M -$41.40M
YoY Change -33.49% -17.57% -27.89%
Net Earnings / Revenue -86.83% -88.19% -86.84%
Basic Earnings Per Share -$0.29 -$0.30 -$0.53
Diluted Earnings Per Share -$0.29 -$0.30 -$533.7K
COMMON SHARES
Basic Shares Outstanding 114.0M 113.3M 79.16M
Diluted Shares Outstanding 114.2M 113.5M 77.57M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $236.8M $260.4M $205.3M
YoY Change 38.58% 26.82% -8.49%
Cash & Equivalents $80.89M $84.06M $153.3M
Short-Term Investments $155.9M $176.3M $52.06M
Other Short-Term Assets $18.66M $19.13M $29.14M
YoY Change -41.82% -34.34% 185.64%
Inventory $3.672M $3.827M $3.874M
Prepaid Expenses $12.21M
Receivables $32.28M $35.20M $24.99M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $291.4M $318.5M $276.5M
YoY Change 20.18% 15.19% 8.23%
LONG-TERM ASSETS
Property, Plant & Equipment $6.062M $849.0K $1.544M
YoY Change 334.55% -45.01% -22.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $387.0K $634.0K $8.438M
YoY Change -93.0% -92.49% 1105.43%
Total Long-Term Assets $6.449M $7.259M $17.50M
YoY Change -54.04% -58.52% -9.78%
TOTAL ASSETS
Total Short-Term Assets $291.4M $318.5M $276.5M
Total Long-Term Assets $6.449M $7.259M $17.50M
Total Assets $297.8M $325.8M $294.0M
YoY Change 16.12% 10.8% 6.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.287M $9.045M $3.440M
YoY Change 35.01% 162.94% 13.16%
Accrued Expenses $54.89M $47.03M $58.37M
YoY Change -2.62% -19.43% 4.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $58.93M $61.56M $66.34M
YoY Change -5.78% -7.21% 6.98%
LONG-TERM LIABILITIES
Long-Term Debt $303.2M $303.0M $302.5M
YoY Change 0.17% 0.18% 25.1%
Other Long-Term Liabilities $6.935M $1.085M $8.286M
YoY Change -8.56% -86.91% -22.56%
Total Long-Term Liabilities $310.2M $1.085M $310.8M
YoY Change -0.04% -99.65% 23.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $58.93M $61.56M $66.34M
Total Long-Term Liabilities $310.2M $1.085M $310.8M
Total Liabilities $369.1M $371.0M $377.1M
YoY Change -1.0% -1.63% 19.89%
SHAREHOLDERS EQUITY
Retained Earnings -$1.411B -$1.378B -$1.220B
YoY Change 11.16% 12.95% 9.72%
Common Stock $1.340B $1.333B $1.137B
YoY Change 16.21% 17.28% 6.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$71.25M -$45.17M -$83.08M
YoY Change
Total Liabilities & Shareholders Equity $297.8M $325.8M $294.0M
YoY Change 16.12% 10.8% 6.96%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$32.63M -$34.13M -$41.40M
YoY Change -33.49% -17.57% -27.89%
Depreciation, Depletion And Amortization $83.00K $290.0K $177.0K
YoY Change -44.3% 63.84% -24.68%
Cash From Operating Activities -$25.70M -$18.91M -$59.20M
YoY Change -26.88% -68.06% 11.93%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $79.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $21.17M -$32.39M -$13.96M
YoY Change -157.85% 132.07% -132.31%
Cash From Investing Activities $21.17M -$32.39M -$14.04M
YoY Change -157.85% 130.77% -132.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 860.0K 0.000 30.78M
YoY Change -34.5% -100.0% 188.34%
NET CHANGE
Cash From Operating Activities -25.70M -18.91M -59.20M
Cash From Investing Activities 21.17M -32.39M -14.04M
Cash From Financing Activities 860.0K 0.000 30.78M
Net Change In Cash -3.668M -51.34M -42.54M
YoY Change -94.79% 20.7% -4917.55%
FREE CASH FLOW
Cash From Operating Activities -$25.70M -$18.91M -$59.20M
Capital Expenditures $0.00 $0.00 $79.00K
Free Cash Flow -$25.70M -$18.91M -$59.28M
YoY Change -26.88% -68.1% 12.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36167
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Karyopharm Therapeutics Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3931704
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
85 Wells Avenue, 2nd Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Newton
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02459
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
658-0600
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
KPTI
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114010448
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84062000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135188000
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001503802
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
176322000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
142779000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
35200000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
47086000
CY2023Q1 us-gaap Inventory Net
InventoryNet
3827000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4224000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18284000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19821000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
846000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1064000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
318541000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
350162000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
849000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1139000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5776000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6238000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
634000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
633000
CY2023Q1 us-gaap Assets
Assets
325800000
CY2022Q4 us-gaap Assets
Assets
358172000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
9045000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2773000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
47032000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58415000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2977000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2872000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2501000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1848000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
61555000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65908000
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
170306000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
170105000
CY2023Q1 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132718000
CY2022Q4 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132718000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5310000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6097000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1085000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q1 us-gaap Liabilities
Liabilities
370974000
CY2022Q4 us-gaap Liabilities
Liabilities
374828000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
113971000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113971000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
113213000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113213000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1333298000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1327909000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-419000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
638000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1378065000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1343939000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-45174000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
325800000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
358172000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38698000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
47670000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32339000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42062000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35907000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38768000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
69597000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
82256000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30899000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34586000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2849000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
74000
CY2023Q1 us-gaap Interest Expense
InterestExpense
5758000
CY2022Q1 us-gaap Interest Expense
InterestExpense
6684000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-264000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-73000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3173000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6683000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34072000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41269000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
130000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34126000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-41399000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113481000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113481000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77570000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77570000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34126000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-41399000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
186000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-90000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33907000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41503000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-34126000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-41399000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5389000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7336000
CY2023Q1 us-gaap Depreciation
Depreciation
290000
CY2022Q1 us-gaap Depreciation
Depreciation
177000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
201000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
198000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1126000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-45000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11886000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2495000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-397000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-232000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1537000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15600000
CY2023Q1 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-462000
CY2022Q1 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-397000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6272000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1837000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9414000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9387000
CY2023Q1 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-682000
CY2022Q1 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-536000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18910000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59197000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
27944000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21584000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
60332000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
35540000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32388000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14035000
CY2023Q1 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
0
CY2022Q1 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
29316000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1467000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30783000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-45000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-90000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51343000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42539000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136885000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197445000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85542000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154906000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84062000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153256000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
846000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1014000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
634000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
636000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85542000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154906000
CY2023Q1 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
923000
CY2022Q1 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
841000
CY2023Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
4076000
CY2022Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
15784000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5389000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
186000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34126000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-45174000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-79673000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1467000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7336000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29294000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-90000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-41399000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-83079000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1124000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1370000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1767000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1878000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
936000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
976000
CY2023Q1 us-gaap Inventory Net
InventoryNet
3827000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4224000
CY2023Q1 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
10410000
CY2022Q1 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
19370000
CY2023Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
253786000
CY2023Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
265906000
CY2022Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
176636000
CY2023Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
20000
CY2023Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
334000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
176322000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
143123000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
4000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
348000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
142779000
CY2023Q1 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2023Q1 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
67
CY2022Q4 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
60
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
149692000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
334000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
149692000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
334000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
129131000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
348000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
129131000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
348000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5389000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7336000
CY2023Q1 kpti Debt Instrument Convertible Threshold Measurement Period Description
DebtInstrumentConvertibleThresholdMeasurementPeriodDescription
during the five-business day period immediately after any five consecutive trading day period
CY2023Q1 us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
5
CY2023Q1 kpti Principal Amount Of Notes Used In Conversion Rate
PrincipalAmountOfNotesUsedInConversionRate
1000
CY2023Q1 kpti Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock
DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
0.98

Files In Submission

Name View Source Status
0000950170-23-017483-index-headers.html Edgar Link pending
0000950170-23-017483-index.html Edgar Link pending
0000950170-23-017483.txt Edgar Link pending
0000950170-23-017483-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img178056270_0.jpg Edgar Link pending
img178979791_0.jpg Edgar Link pending
img179903312_0.jpg Edgar Link pending
img179903312_1.jpg Edgar Link pending
img180826833_0.jpg Edgar Link pending
img181750354_0.jpg Edgar Link pending
kpti-20230331.htm Edgar Link pending
kpti-20230331.xsd Edgar Link pending
kpti-ex10_3.htm Edgar Link pending
kpti-ex10_4.htm Edgar Link pending
kpti-ex10_5.htm Edgar Link pending
kpti-ex10_6.htm Edgar Link pending
kpti-ex10_7.htm Edgar Link pending
kpti-ex10_8.htm Edgar Link pending
kpti-ex10_9.htm Edgar Link pending
kpti-ex31_1.htm Edgar Link pending
kpti-ex31_2.htm Edgar Link pending
kpti-ex32_1.htm Edgar Link pending
kpti-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kpti-20230331_def.xml Edgar Link unprocessable
kpti-20230331_lab.xml Edgar Link unprocessable
kpti-20230331_pre.xml Edgar Link unprocessable
kpti-20230331_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
kpti-20230331_cal.xml Edgar Link unprocessable